Analyst Highlights Aclaris Therapeutics ' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations

Wednesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topical "soft" JAK 1/3 inhibitor, in patients with mild to severe atopic dermatitis (eczema). The trial met the primary efficacy endpoint, the percent change from…#eczema #eczemaarea #bid #oncedaily #williamblair
Source: Reuters: Health - Category: Consumer Health News Source Type: news